Eli Lilly & Co: Live from the Big Easy: Retatrutide moves the goal posts; LLY event highlights breadth of pipeline

Research evidence excerpt

Eli Lilly & Co: Live from the Big Easy: Retatrutide moves the goal posts; LLY event highlights breadth of pipeline

Equity Research

U.S. Biopharmaceuticals

7 June 2026

Eli Lilly & Co

Live from the Big Easy: Retatrutide

moves the goal posts; LLY event

LLY OVERWEIGHThighlights breadth of pipeline

U.S. Biopharmaceuticals NEUTRAL

At Saturday's symposium for the first two P3 presentations of Price Target USD 1400.00

retatrutide, the asset delivered on the promise of moving the Price (05-Jun-26) USD 1131.42

goal posts in what's possible in obesity pharmacotherapy. PotentialSource: Bloomberg,Upside/DownsideBarclays Research +23.7%

LLY's investor event Saturday evening highlighted that there's

U.S. Biopharmaceuticalsa lot more to come.

Emily Field, CFA

+1 212 526 4160

emily.field@barclays.com

BCI, US

Hang Hu, PhD THE 2026 EXTEL SURVEY IS NOW OPEN

+1 212 526 6364

Support our industry-leading analysts with 5-Star hang.hu@barclays.comBCI, US

Alexandre Bouilloux votes in this year’s Extel All-America Research

+1 212 526 9937

Survey alexandre.bouilloux@barclays.com

Xiao Guo

Vote Now View Analysts +1 212 526 9609

xiao.guo@barclays.com

Retatrutide delivers at ADA: Though headline numbers for the first P3 study of key LLY pipeline

asset retatrutide were disclosed just a few short weeks ago (and the tight timetable whereby the

data was received relative to the ADA Scientific Sessions prevented the concurrent publication

in a scientific publication (see: Eli Lilly & Co: Retatrutide delivers in TRIUMPH-1 as top efficacy

option in high BMIs; full data to come at ADA (05/21/26)), in our view the presentation of the full

TRANSCEND-T2D-1 data (treatment-naive type 2 diabetes patients) and TRIUMPH-1 data

(patients with overweight/obesity without T2D) on Saturday delivered on the promise of the